ALNY News and Press, Alnylam Pharmaceuticals Inc. From 05/02/24

− Achieved First Quarter 2024 Global Net Product Revenues of $365 Million, Representing 32% Year-Over-Year Growth Compared to Q1 2023, Including Continued Momentum from Total TTR Delivering 29% Year-Over-Year Growth – − Demonstrated Strong Progress with Zilebesiran Hy...

Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...

2024-05-01 22:07:03 ET Summary Baillie Gifford's 13F portfolio value increased from ~$126B to ~$129B this quarter. The top three holdings in the portfolio are NVIDIA, MercadoLibre, and Amazon.com. Baillie Gifford made stake increases in Coupang, Meta Platforms, NU Holdings, an...

2024-05-01 11:40:08 ET More on Alnylam Pharmaceuticals Is Alnylam's HELIOS-B Delay A Red Flag? Alnylam Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2023 Earnings Call Transcript Alnylam, Roche ma...

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia PR Newswire The expanded partnership will allow Alnylam a...

2024-04-29 07:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Management will provide an update on the C...

2024-04-10 12:03:39 ET More on Ionis Pharmaceuticals Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain Ionis Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Ionis Pharmaceuticals, Inc. (IONS) Q4 2023 Earnings Call Transc...

– Study Met Primary Endpoint Demonstrating Clinically Significant Additive Reductions in Ambulatory Systolic Blood Pressure of Up to 12.1 mmHg Across Three Independent Study Cohorts at Month 3 – – A Single Dose of Zilebesiran Resulted in Clinically Significant Additiv...

2024-04-03 11:57:45 ET Summary Enrollment paused in the Verve Therapeutics' phase 1b heart-1 study, using VERVE-101 for the treatment of patients with heterozygous familial hypercholesterolemia after a Grade 3 adverse event. Despite VERVE-101 setback, the ability to move forward w...